Education
About Us
Working with TipRanks
Follow Us
Stanley C Erck Insider Profile
4 Followers
Stanley C Erck, Director at MaxCyte, holds 398.33K shares in MaxCyte (Ticker: GB:MXCT). Most recently, Stanley C Erck Bought 100,000 shares of MaxCyte on Aug 13, 2025 for an estimated value of 137.22K.
Stanley C Erck MaxCyte (MXCT)Director
MaxCyte (MXCT)
Director
Not Ranked
Stanley C Erck has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Stanley C Erck does not currently own shares as a corporate insider.
A breakdown of Stanley C Erck's holdings
Insider Roles
Stanley C Erck does not currently hold a role as a corporate insider.
Roles that Stanley C Erck holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Stanley C Erck
Stanley C Erck's Trading History
List of latest transactions for each holding click on a transaction to see Stanley C Erck's performance on stock
You May Also Like
Stanley C Erck insider profile FAQ
What is the percentage of profitable transactions made by Stanley C Erck?
The percentage of profitable transactions made by Stanley C Erck is ―.
What is the average return per transaction made by Stanley C Erck?
The average return per transaction made by Stanley C Erck is ―.
What stocks does Stanley C Erck hold?
Stanley C Erck holds: GB:MXCT stocks.
What was Stanley C Erck’s latest transaction?
Stanley C Erck latest transaction was an Informative Buy of 137.22K.
What was Stanley C Erck's most profitable transaction?
Stanley C Erck’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Stanley C Erck's role in MaxCyte?
Stanley C Erck's role in MaxCyte is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.